Early clinical research
SX-682 + nivolumab — RAS-mutant MSS unresectable CRC
SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer
- Phase
- Phase I/II
- Recruitment
- Active, not recruiting
- Results maturity
- No results
- Publication
- No publication
- Regulatory approval
- No regulatory approval
- NCT
- NCT04599140
- Registry checked
- 2026-10-29
- Editorial update
- 2026-10-29
Not a treatment recommendation. Experimental or ongoing research does not by itself replace standard care.
For patients
What is being studied? A new combination is being tested in a genetic group where immunotherapy usually does not work well.
Why promising? Early clinical test of CXCR1/2 inhibition to overcome IO resistance in MSS CRC.
What is not proven? Clinical efficacy; phase III; do not confuse with dMMR IO results.
Is this standard care today? This listing alone does not replace standard care; approval and guideline context require clinician judgment.
For clinicians
Early phase (I/II); enrollment closed.
Cancer / population: Colon, Rectum — RAS mutant, MSS unresectable/metastatik CRC
Intervention: SX-682 (CXCR1/2) + nivolumab
Primary endpoint: Güvenlik / erken etkinlik
Limitations: Erken faz; MSS popülasyonunda IO beklentisi düşük tutulmalı.